Summary

for people ages 40 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion

Description

Summary

The purpose of this study is to assess the long-term safety and efficacy of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

Keywords

Progressive Supranuclear Palsy (PSP)tauopathySteele-Richardson-Olszewski SyndromePSPSupranuclear Palsy, ProgressiveABBV-8E12

Eligibility

You can join if…

Open to people ages 40 years and up

  • Subject completed the 52-week treatment period in Study M15-562 (NCT02985879).
  • In the opinion of the investigator, the subject was compliant during participation in Study M15-562 (NCT02985879).
  • Subject has an identified, reliable, study partner (e.g., caregiver, family member, social worker, or friend).

You CAN'T join if...

  • Subjects who weigh less than 44 kg (97 lbs) at the time of study entry.
  • Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI).
  • Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results.
  • More than 8 weeks have elapsed since the subject received his/her last dose of study drug in Study M15-562 (NCT02985879).
  • Subject is considered by the investigator, for any reason, to be an unsuitable candidate to receive ABBV-8E12 or the subject is considered by the investigator to be unable or unlikely to comply with the dosing schedule or study evaluations.

Locations

  • Univ California, San Francisco /ID# 165553
    San FranciscoCalifornia94143-2204United States
  • University of California, Los Angeles /ID# 165669
    Los AngelesCalifornia90095United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT03391765
Phase
Phase 2
Study Type
Interventional
Last Updated